AspenBio Pharma, Inc. to Host Investor Update Call Today at 4:30 PM ET

CASTLE ROCK, CO--(Marketwire - March 12, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, announced the company will hold a conference call today, March 12, 2009 at 4:30 p.m. Eastern Time, to discuss updates, developments and plans for its AppyScore FDA 510 (k) registration. The call will be followed by a question and answer period. The call will be hosted by Daryl Faulkner, the company's chief executive officer; Dr. Robert Caspari, the COO and chief medical officer and Dr. Mark Colgin, the company's chief scientific officer.

Parties who are interested in hearing the call are asked to dial into the conference telephone number 5-10 minutes prior to the start time:

U.S./Canada: 800-895-0231
International: 785-424-1054

An operator will register your name and organization and ask you to wait until the call begins. If you have any difficulty connecting with the conference call, please contact the Liolios Group at 949-574-3860.

An audio replay of the call will be available for seven days following the call:

U.S./Canada: 800-723-0479
International: 402-220-2650

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture and marketing of novel proprietary products. The company continues to advance development and testing of its blood-based human diagnostic tests designed as an aid in the diagnosis of human appendicitis. AspenBio Pharma was originally formed to produce purified proteins for diagnostic applications and has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. For more information, go to http://www.aspenbiopharma.com.